|
1.
Share Success: Letters From Readers
Letter
I: From Sal
Received
at Testimonial
Submit Form Friday, July 7, 2017 at 15:22:42
(Unedited)
Hi, my name is Sal. I can HIGHLY RECOMMEND THIS PRODUCT for heel spurs!
I have been taking it for 1 1/2 years, and my memory recalls that when I first got started, the heel pain was 95% gone within ONE WEEK!
I suggested it to my Brother In Law for heel spurs and a friend for shoulder pain. They both have been taking it continually for better than a year. None of us consider "going off of it". Why should we, it works!
Does not cost an "arm & a leg" so why not! Thank you for creating it for us to use to get rid of the pain that causes us so-o-o much discomfort.
Letter
II: From Julie S.
Received
at Customer Service May 14 at 9:23 AM
(Unedited)
Hello,
I am very thankful to this particular calcium supplement as it continues to help me with my arthritis and osteoporosis.
I am an old woman who took this calcium aspartate anhydrous for the first time in 2012. Due to this ezorb calcium I am able to move without a problem, rise from bed without any pain, do my 10 minute daily yoga poses with ease and continue my daily routine with agility of movement.
I am now 71 years old and am proud to say that I consider myself very lucky for having known this supplement which brought a lot of relief and good in my life. I have no side effects.
I continue to take it daily and will continue to do so in the many more years I am here. To those who originated the making of this supplement, kudos to you as you help me enjoy my life tremendously.
Sincerely,
Julie
***************************************************
From
the Desk of EZorb Newsletter Editor:
This
newsletter is now read by over 95,000 subscribers
worldwide. Success stories you have contributed over
the years have had a great impact on many people's
quality of life. Your continuous support will be
greatly appreciated by tens of thousands who have been
suffering and would continuously suffer, without your
help! Please email your
story to sharesuccess @ ezorbonline.com
or simply post it at Testimonial
Submit Form. Your personal information will never be
revealed to the public. If your testimonial is selected for publication, you will receive a gift to show
our appreciation of your effort.
2.
Research News: Obesity Associated With Joint Replacement Surgery
Study results suggest that maintaining a healthy bodyweight may reduce the risk for mobility limitation in later life among older women who undergo surgical joint replacement for osteoarthritis (OA).
In an analysis of data from the Women's Health Initiative Program linked to Medicare claims records, the researchers found that overweight and obese women aged 65-79 years at baseline who underwent total hip replacement had a significantly increased risk for mobility limitation - defined as health limiting their ability to walk one block or climb one flight stairs by "a lot" or "a little" – at the age of 85 years compared with their normal-weight counterparts.
In all, 37.3% of 335 patients with normal bodyweight (BMI<=24.9 kg/m2) experienced impaired mobility at 85 years, compared with 45.9% of 329 overweight women (BMI=25.0-29.9 kg/m2), 57.1% of 189 women with class I obesity (BMI=30.0-34.9 kg/m2), and 51.7% of 87 patients with class II obesity (BMI>=35.0 kg/m2).
These findings translated into odds ratios (ORs) for mobility limitation of 1.53, 2.40, and 4.37 for women in the overweight, class I obesity, and class II obesity groups, respectively, relative to those with normal bodyweight, report the study authors in Arthritis Care & Research.
Women with class II obesity also had a significantly increased risk for death before the age of 85 years than normal-weight participants (adjusted OR=6.08), but mortality risk was not significantly higher among those who were overweight or had class I obesity.
Furthermore, participants who had a waist circumference (WC) of more than 88 cm were significantly more likely to experience mobility limitation than those who had a WC of 88 cm or smaller (adjusted OR=1.48), suggesting an association between abdominal obesity and impaired mobility. However, there was no significant association between waist-to-hip ratio and mobility limitation or death.
The team also identified a relationship between obesity and late-life mobility limitation among patients undergoing total knee replacement (TKR) for OA, but the association varied with age. For women who had their first TKR at the age of 67-74 years, those who had class I or II obesity had a significantly higher risk for mobility limitation than normal-weight women (OR=2.75 and 3.24, respectively), but among the women who were aged 75-79 at the time of surgery, only those with class II obesity had a significantly increased risk (OR=1.99).
However, women in the TKR group who had a WC of greater than 88 cm had a significantly increased risk for mobility impairment than those with a smaller WC regardless of age (OR=1.55-1.88).
Taken together, "these findings support the maintenance of healthy body weight among women with hip or knee OA scheduled to undergo [total joint replacement] to lessen the burden of mobility loss in late life," say Aladdin Shadyab (University of California San Diego School of Medicine, La Jolla, USA) and fellow researchers.
And they conclude: "Future studies should evaluate whether weight loss before [total joint replacement] for hip or knee OA improves long-term aging outcomes."
Original research was published in 17-10-2017 | Rheumatology | News | Article.
3.
Useful Links
Frequently
Asked Questions & Answers
EZorb
Clinical Studies
Marvlix
Benefits
Order
Now
4.
Calcium
Absorption Test
EZorb
Calcium has set a new world record of absorption rate.
You can compare EZorb with other calcium supplements
by using the simple step-by-step instructions we
provide. E-mail your request to test @ elixirindustry.com
for a copy of the instructions.
5.
What Are Others Saying About EZorb and Marvlix?
EZorb and Marvlix have restored confidence in thousands of men
and women. It has brought happiness and healthy life
to families around the world. Click here
to read what people say about EZorb and Marvlix. |
